<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01377428</url>
  </required_header>
  <id_info>
    <org_study_id>CQAB149BDE03</org_study_id>
    <nct_id>NCT01377428</nct_id>
  </id_info>
  <brief_title>Efficacy of Indacaterol 150 µg Versus Formoterol</brief_title>
  <official_title>A 12-week Treatment, Multicenter, Randomized, Double Blind, Double Dummy, Parallel-group Study to Assess the Efficacy of Indacaterol (150 μg o.d.) in Patients With Chronic Obstructive Pulmonary Disease, Using Formoterol (12 μg b.i.d.) as an Active Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The study will be a 12 week treatment (84 days), parallel group, randomized, double blind,
      double dummy, study to assess the superiority of indacaterol (150 μg o.d.) versus formoterol
      (12 μg b.i.d.) in terms of trough forced expiratory volume in 1 second (FEV1).

      Patients will be enrolled after giving informed consent and then begin a screening/run-in
      period for 14 days. Patients will be randomized to one of two treatment groups using an
      allocation ratio of 1:1 to receive either indacaterol (150 μg o.d.) and placebo to
      formoterol, or formoterol (12 μg b.i.d.) and placebo to indacaterol for a treatment period of
      12 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Anticipated">February 2012</completion_date>
  <primary_completion_date type="Anticipated">February 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>24-h post-dose trough forced expiratory volume in 1 second (FEV1)</measure>
    <time_frame>After 84 days of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>24-h post-dose trough inspiratory capacity (IC)</measure>
    <time_frame>After 84 days of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
  <arm_group>
    <arm_group_label>Indacaterol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Indacaterol 150 µg once daily (od) via single-dose dry powder inhaler (SDDPI)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Formoterol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Formoterol 12 µg twice daily (bid) via single-dose dry powder inhaler (SDDPI)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indacaterol</intervention_name>
    <description>Indacaterol 150 µg once daily (od) via single-dose dry powder inhaler (SDDPI)</description>
    <arm_group_label>Indacaterol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formoterol</intervention_name>
    <description>Formoterol 12 µg twice daily (bid) via single-dose dry powder inhaler (SDDPI)</description>
    <arm_group_label>Formoterol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of COPD (moderate-to-severe as classified by the Global Initiative for
             Chronic Obstructive Lung Disease (GOLD) Guidelines, 2009) and:

               -  Post-bronchodilator FEV1 &lt;80% and ≥40% of the predicted normal value

               -  Post-bronchodilator FEV1/FVC (forced vital capacity) &lt;70%

          -  Smoking history of at least 10 pack-years

        Exclusion Criteria:

          -  Patients who have had a COPD exacerbation in the 6 weeks prior to screening

          -  Patients who have had a respiratory tract infection within 6 weeks prior to screening

          -  Patients with concomitant pulmonary disease

          -  Patients with a history of asthma

          -  Patients with diabetes Type I or uncontrolled diabetes Type II

          -  Any patient with lung cancer or a history of lung cancer

          -  Patients with a history of certain cardiovascular comorbid conditions

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 17, 2011</study_first_submitted>
  <study_first_submitted_qc>June 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2011</study_first_posted>
  <last_update_submitted>April 19, 2017</last_update_submitted>
  <last_update_submitted_qc>April 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>Indacaterol</keyword>
  <keyword>Formoterol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

